title: Risk assessment and management of anthracycline and HER2 receptor inhibitor-induced cardiomyopathy.
abstract: With the advent and increased use of chemotherapeutic agents and radiation therapy, cancer survival rates have increased. With increased survival, both acute and chronic cardiotoxic adverse effects have emerged. The growing need for managing the treatment of individuals with chemotherapy-induced cardiotoxicity has led to the formation of cardio-oncology programs throughout the United States. These programs concentrate on many aspects of cardiac disease in the oncology patient. Of these, the cardiotoxic effects (particularly cardiomyopathy) of anthracyclines and HER2 receptor inhibitors are a large focus of cardio-oncology practice. Despite the increasing availability of these programs, no consensus guidelines have been established to provide a framework for treating these patients. This review describes the initial evaluation, risk assessment, and management of individuals receiving anthracycline and HER2 receptor inhibitor therapy for cardiomyopathy. These recommendations are supported by the current literature in this field.
authors: From the John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, Department of Internal Medicine, and the Department of Hematology and Oncology, Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, Louisiana.
authors: Eiman
authors: E
authors: Jahangir
authors: From the John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, Department of Internal Medicine, and the Department of Hematology and Oncology, Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, Louisiana.
authors: Sangeeta
authors: S
authors: Shah
authors: From the John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, Department of Internal Medicine, and the Department of Hematology and Oncology, Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, Louisiana.
authors: Kelly
authors: K
authors: Shum
authors: From the John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, Department of Internal Medicine, and the Department of Hematology and Oncology, Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, Louisiana.
authors: Caitlin
authors: C
authors: Baxter
authors: From the John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, Department of Internal Medicine, and the Department of Hematology and Oncology, Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, Louisiana.
authors: Jill D
authors: JD
authors: Fitzpatrick
authors: From the John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, Department of Internal Medicine, and the Department of Hematology and Oncology, Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, Louisiana.
authors: John
authors: J
authors: Cole
authors: From the John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, Department of Internal Medicine, and the Department of Hematology and Oncology, Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, Louisiana.
authors: Yvonne
authors: Y
authors: Gilliland
authors: From the John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, Department of Internal Medicine, and the Department of Hematology and Oncology, Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, Louisiana.
authors: Nichole M
authors: NM
authors: Polin
mesh_terms: D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D018570:Risk Assessment
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human